특이적 결합 분자

본 발명은 생식세포 암 항원 MAGEA1로부터 유래된 HLA-A*02 제한 펩타이드 KVLEYVIKV (서열 번호: 1)에 결합하는 T 세포 수용체 (TCR)와 같은 특이적 결합 분자에 관한 것이다. 특이적 결합 분자는 고유 MAGEA1 TCR에 비해 알파 및/또는 베타 가변 도메인 내의 비-천연 돌연변이를 포함할 수 있다. 본 발명의 특이적 결합 분자는 악성 질환의 치료를 위한 신규 면역치료 시약으로서 사용하기에 특히 적합하다. The present invention relates to specific binding molecul...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: DIAS DO NASCIMENTO JORGE, JAMES PETER, O'DWYER RONAN, HAYES CONOR, CHILLAKURI CHANDRAMOULI, PARKER JAMES, POOLE ANDREW
Format: Patent
Sprache:kor
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator DIAS DO NASCIMENTO JORGE
JAMES PETER
O'DWYER RONAN
HAYES CONOR
CHILLAKURI CHANDRAMOULI
PARKER JAMES
POOLE ANDREW
description 본 발명은 생식세포 암 항원 MAGEA1로부터 유래된 HLA-A*02 제한 펩타이드 KVLEYVIKV (서열 번호: 1)에 결합하는 T 세포 수용체 (TCR)와 같은 특이적 결합 분자에 관한 것이다. 특이적 결합 분자는 고유 MAGEA1 TCR에 비해 알파 및/또는 베타 가변 도메인 내의 비-천연 돌연변이를 포함할 수 있다. 본 발명의 특이적 결합 분자는 악성 질환의 치료를 위한 신규 면역치료 시약으로서 사용하기에 특히 적합하다. The present invention relates to specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide KVLEYVIKV (SEQ ID NO: 1) derived from the germline cancer antigen MAGEA1. The specific binding molecules may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGEA1 TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_KR20220087511A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>KR20220087511A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_KR20220087511A3</originalsourceid><addsrcrecordid>eNrjZBB_27XzzdwtbxY0KrzatOHt1JUKr7e1vJk3gYeBNS0xpziVF0pzMyi7uYY4e-imFuTHpxYXJCan5qWWxHsHGRkYGRkYWJibGho6GhOnCgD9mylC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>특이적 결합 분자</title><source>esp@cenet</source><creator>DIAS DO NASCIMENTO JORGE ; JAMES PETER ; O'DWYER RONAN ; HAYES CONOR ; CHILLAKURI CHANDRAMOULI ; PARKER JAMES ; POOLE ANDREW</creator><creatorcontrib>DIAS DO NASCIMENTO JORGE ; JAMES PETER ; O'DWYER RONAN ; HAYES CONOR ; CHILLAKURI CHANDRAMOULI ; PARKER JAMES ; POOLE ANDREW</creatorcontrib><description>본 발명은 생식세포 암 항원 MAGEA1로부터 유래된 HLA-A*02 제한 펩타이드 KVLEYVIKV (서열 번호: 1)에 결합하는 T 세포 수용체 (TCR)와 같은 특이적 결합 분자에 관한 것이다. 특이적 결합 분자는 고유 MAGEA1 TCR에 비해 알파 및/또는 베타 가변 도메인 내의 비-천연 돌연변이를 포함할 수 있다. 본 발명의 특이적 결합 분자는 악성 질환의 치료를 위한 신규 면역치료 시약으로서 사용하기에 특히 적합하다. The present invention relates to specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide KVLEYVIKV (SEQ ID NO: 1) derived from the germline cancer antigen MAGEA1. The specific binding molecules may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGEA1 TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.</description><language>kor</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220624&amp;DB=EPODOC&amp;CC=KR&amp;NR=20220087511A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220624&amp;DB=EPODOC&amp;CC=KR&amp;NR=20220087511A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DIAS DO NASCIMENTO JORGE</creatorcontrib><creatorcontrib>JAMES PETER</creatorcontrib><creatorcontrib>O'DWYER RONAN</creatorcontrib><creatorcontrib>HAYES CONOR</creatorcontrib><creatorcontrib>CHILLAKURI CHANDRAMOULI</creatorcontrib><creatorcontrib>PARKER JAMES</creatorcontrib><creatorcontrib>POOLE ANDREW</creatorcontrib><title>특이적 결합 분자</title><description>본 발명은 생식세포 암 항원 MAGEA1로부터 유래된 HLA-A*02 제한 펩타이드 KVLEYVIKV (서열 번호: 1)에 결합하는 T 세포 수용체 (TCR)와 같은 특이적 결합 분자에 관한 것이다. 특이적 결합 분자는 고유 MAGEA1 TCR에 비해 알파 및/또는 베타 가변 도메인 내의 비-천연 돌연변이를 포함할 수 있다. 본 발명의 특이적 결합 분자는 악성 질환의 치료를 위한 신규 면역치료 시약으로서 사용하기에 특히 적합하다. The present invention relates to specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide KVLEYVIKV (SEQ ID NO: 1) derived from the germline cancer antigen MAGEA1. The specific binding molecules may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGEA1 TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBB_27XzzdwtbxY0KrzatOHt1JUKr7e1vJk3gYeBNS0xpziVF0pzMyi7uYY4e-imFuTHpxYXJCan5qWWxHsHGRkYGRkYWJibGho6GhOnCgD9mylC</recordid><startdate>20220624</startdate><enddate>20220624</enddate><creator>DIAS DO NASCIMENTO JORGE</creator><creator>JAMES PETER</creator><creator>O'DWYER RONAN</creator><creator>HAYES CONOR</creator><creator>CHILLAKURI CHANDRAMOULI</creator><creator>PARKER JAMES</creator><creator>POOLE ANDREW</creator><scope>EVB</scope></search><sort><creationdate>20220624</creationdate><title>특이적 결합 분자</title><author>DIAS DO NASCIMENTO JORGE ; JAMES PETER ; O'DWYER RONAN ; HAYES CONOR ; CHILLAKURI CHANDRAMOULI ; PARKER JAMES ; POOLE ANDREW</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_KR20220087511A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>kor</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>DIAS DO NASCIMENTO JORGE</creatorcontrib><creatorcontrib>JAMES PETER</creatorcontrib><creatorcontrib>O'DWYER RONAN</creatorcontrib><creatorcontrib>HAYES CONOR</creatorcontrib><creatorcontrib>CHILLAKURI CHANDRAMOULI</creatorcontrib><creatorcontrib>PARKER JAMES</creatorcontrib><creatorcontrib>POOLE ANDREW</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DIAS DO NASCIMENTO JORGE</au><au>JAMES PETER</au><au>O'DWYER RONAN</au><au>HAYES CONOR</au><au>CHILLAKURI CHANDRAMOULI</au><au>PARKER JAMES</au><au>POOLE ANDREW</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>특이적 결합 분자</title><date>2022-06-24</date><risdate>2022</risdate><abstract>본 발명은 생식세포 암 항원 MAGEA1로부터 유래된 HLA-A*02 제한 펩타이드 KVLEYVIKV (서열 번호: 1)에 결합하는 T 세포 수용체 (TCR)와 같은 특이적 결합 분자에 관한 것이다. 특이적 결합 분자는 고유 MAGEA1 TCR에 비해 알파 및/또는 베타 가변 도메인 내의 비-천연 돌연변이를 포함할 수 있다. 본 발명의 특이적 결합 분자는 악성 질환의 치료를 위한 신규 면역치료 시약으로서 사용하기에 특히 적합하다. The present invention relates to specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide KVLEYVIKV (SEQ ID NO: 1) derived from the germline cancer antigen MAGEA1. The specific binding molecules may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGEA1 TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language kor
recordid cdi_epo_espacenet_KR20220087511A
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title 특이적 결합 분자
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T12%3A07%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DIAS%20DO%20NASCIMENTO%20JORGE&rft.date=2022-06-24&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EKR20220087511A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true